Tomorrow.bio 'pivots' from cryonics to preventive longevity

Berlin-based Tomorrow Biostasis GmbH — better known as Tomorrow.bio — is widening its remit. The company that built a business around cryopreservation is launching a paid longevity service that pairs preventive medical guidance with its existing cryonics offering, a move it says makes it "the world’s first REAL life extension company."

In a February 18 announcement, Tomorrow.bio’s founder Joana Vargas said the organisation is introducing a team of "Longevity Doctors and Experts" who will give members evidence-based, prevention-focused care aimed at increasing maximal lifespan. "Starting now, we are adding a dedicated team to help you live as long as possible," Joana Vargas wrote in Tomorrow.bio's announcement.

The new service sits alongside the company’s core cryopreservation product. Vargas framed cryonics as a high-quality safety net: preventive medicine first, cryopreservation as backup. "Cryopreservation is still an important safety net, and we provide the highest quality one around," the announcement reads.

Members will receive one-on-one guidance from the company’s longevity experts focused on translating existing medical research into actionable plans: assessing biological ageing, identifying major risks and recommending realistic interventions to extend lifespan. Tomorrow.bio also promotes communal incentives — reduced membership fees for invited friends and family who want to prioritise longevity alongside cryopreservation planning.

Commercially, the company continues to sell memberships and long-term storage plans.

Tomorrow.bio’s shift is pragmatic: combine subscription-based longevity services with an existing, more speculative cryopreservation business to diversify revenue and broaden appeal.

Whether it will convert those preventive-care clients into long-term cryonics backers — or attract the regulatory approvals, clinical rigor and technical advances needed to make revival plausible — remains an open question.